PATTIES FOODS - Frankfurt Stock Exchang (PH4) - Total Liabilities

Latest as of June 2025: €876.86 Million EUR ≈ $1.03 Billion USD

Based on the latest financial reports, PATTIES FOODS - Frankfurt Stock Exchang (PH4) has total liabilities worth €876.86 Million EUR (≈ $1.03 Billion USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore PATTIES FOODS - Frankfurt Stock Exchang cash flow conversion to assess how effectively this company generates cash.

PATTIES FOODS - Frankfurt Stock Exchang - Total Liabilities Trend (2020–2024)

This chart illustrates how PATTIES FOODS - Frankfurt Stock Exchang's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of PATTIES FOODS - Frankfurt Stock Exchang to evaluate the company's liquid asset resilience ratio.

PATTIES FOODS - Frankfurt Stock Exchang Competitors by Total Liabilities

The table below lists competitors of PATTIES FOODS - Frankfurt Stock Exchang ranked by their total liabilities.

Company Country Total Liabilities
Advanced Wireless Semiconductor Co
TWO:8086
Taiwan NT$2.29 Billion
Hidrovias do Brasil S.A
SA:HBSA3
Brazil R$4.33 Billion
BEH Property Co Ltd
SHG:600791
China CN¥13.77 Billion
PMB Technology Bhd
KLSE:7172
Malaysia RM1.22 Billion
Hangzhou MDK Opto Electronic Corp. Ltd. A
SHG:688079
China CN¥1.92 Billion
Henan Ancai Hi-tech Co Ltd
SHG:600207
China CN¥4.02 Billion
Irish Continental Group PLC
IR:IR5B
Ireland €393.60 Million
Sparebanken Sor
OL:SOR
Norway Nkr158.47 Billion

Liability Composition Analysis (2020–2024)

This chart breaks down PATTIES FOODS - Frankfurt Stock Exchang's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PATTIES FOODS - Frankfurt Stock Exchang (PH4) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.44 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 2.78 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.74 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how PATTIES FOODS - Frankfurt Stock Exchang's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for PATTIES FOODS - Frankfurt Stock Exchang (2020–2024)

The table below shows the annual total liabilities of PATTIES FOODS - Frankfurt Stock Exchang from 2020 to 2024.

Year Total Liabilities Change
2024-12-31 €1.03 Billion
≈ $1.20 Billion
-14.57%
2023-12-31 €1.21 Billion
≈ $1.41 Billion
+1.35%
2022-12-31 €1.19 Billion
≈ $1.39 Billion
+11.71%
2021-12-31 €1.06 Billion
≈ $1.24 Billion
+31.69%
2020-12-31 €808.29 Million
≈ $944.98 Million
--

About PATTIES FOODS - Frankfurt Stock Exchang

F:PH4 Germany Biotechnology
Market Cap
$1.69 Billion
€1.44 Billion EUR
Market Cap Rank
#9631 Global
#1170 in Germany
Share Price
€0.99
Change (1 day)
-1.99%
52-Week Range
€0.28 - €1.35
All Time High
€1.35
About

CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junctio… Read more